Skip to main content

Table 1 Carbapenem usage before and after intervention

From: Impact of hospital formulary intervention on carbapenem use: a segmented time-series analysis of consumption and a propensity score-matched non-inferiority study of treatment efficacy

 

Before

After

n

1835

1608

Sex = female, n (%)

694

(37.8)

674

(41.9)

Age, mean (SD)

63.0

(19.9)

62.3

(21.3)

Medication, n (%)

MEPM

1577

(85.9)

1451

(90.2)

  Internal Medicine

580

(31.6)

558

(34.7)

  Surgery

750

(40.9)

558

(34.7)

   Gastrointestinal Surgery

530

(28.9)

353

(22.0)

  Others

247

(13.5)

334

(20.8)

DRPM

198

(10.8)

79

(4.9)

  Internal Medicine

27

(1.5)

14

(0.9)

  Surgery

103

(5.6)

20

(1.2)

   Gastrointestinal Surgery

102

(5.5)

19

(1.2)

 Others

68

(3.7)

45

(2.8)

IPM/CS

60

(3.3)

78

(4.9)

  Internal Medicine

14

(0.8)

18

(1.1)

  Surgery

34

(1.9)

40

(2.5)

   Gastrointestinal Surgery

4

(0.2)

24

(1.5)

 Others

12

(0.7)

20

(1.2)

Treatment duration days, mean (SD)

8.4

(7.6)

7.3

(6.5)

  1. MEPM, meropenem; DRPM, doripenem; IPM/CS, imipenem/cilastatin